S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
pixel
Dems push Biden climate, health priorities toward Senate OK
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as grain leaves Ukraine; plant hit
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
pixel
Dems push Biden climate, health priorities toward Senate OK
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as grain leaves Ukraine; plant hit
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
pixel
Dems push Biden climate, health priorities toward Senate OK
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as grain leaves Ukraine; plant hit
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
pixel
Dems push Biden climate, health priorities toward Senate OK
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as grain leaves Ukraine; plant hit
pixel
NASDAQ:APLS

Apellis Pharmaceuticals - APLS Stock Forecast, Price & News

$63.33
+2.00 (+3.26%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$59.44
$63.50
50-Day Range
$38.87
$63.33
52-Week Range
$27.50
$67.74
Volume
780,317 shs
Average Volume
1.32 million shs
Market Capitalization
$6.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$70.36

Apellis Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
11.1% Upside
$70.36 Price Target
Short Interest
Healthy
8.80% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.62
Upright™ Environmental Score
News Sentiment
-0.83mentions of Apellis Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$4.75 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.67) to ($4.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

755th out of 1,283 stocks

Pharmaceutical Preparations Industry

365th out of 615 stocks

APLS stock logo

About Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on APLS shares. The Goldman Sachs Group reduced their target price on Apellis Pharmaceuticals from $94.00 to $84.00 and set a "buy" rating on the stock in a report on Tuesday, May 24th. Raymond James lowered their target price on Apellis Pharmaceuticals from $114.00 to $102.00 in a research report on Thursday, May 5th. Credit Suisse Group raised their target price on Apellis Pharmaceuticals to $49.00 in a research report on Friday, May 20th. Citigroup raised their target price on Apellis Pharmaceuticals from $81.00 to $86.00 and gave the stock a "buy" rating in a research report on Wednesday, July 20th. Finally, Roth Capital lowered Apellis Pharmaceuticals from a "neutral" rating to a "sell" rating and set a $40.00 price objective for the company. in a research report on Wednesday, April 13th. One analyst has rated the stock with a sell rating, two have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $70.36.

Apellis Pharmaceuticals Stock Performance

Shares of NASDAQ:APLS opened at $63.33 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.58 and a current ratio of 8.85. The stock's 50 day moving average price is $47.76 and its 200-day moving average price is $46.36. Apellis Pharmaceuticals has a twelve month low of $27.50 and a twelve month high of $67.74.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Rating) last posted its quarterly earnings results on Wednesday, May 4th. The company reported ($1.42) EPS for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). The company had revenue of $14.38 million during the quarter, compared to the consensus estimate of $12.81 million. Apellis Pharmaceuticals had a negative return on equity of 607.37% and a negative net margin of 866.81%. During the same period last year, the firm posted ($2.32) EPS. As a group, equities analysts predict that Apellis Pharmaceuticals will post -5.67 EPS for the current year.

Insider Buying and Selling

In related news, insider Victoria L. Brown sold 2,698 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Friday, June 17th. The shares were sold at an average price of $45.00, for a total value of $121,410.00. Following the sale, the insider now owns 24,974 shares of the company's stock, valued at approximately $1,123,830. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Adam J. Townsend sold 5,000 shares of the business's stock in a transaction on Wednesday, August 3rd. The shares were sold at an average price of $56.43, for a total transaction of $282,150.00. Following the completion of the transaction, the insider now directly owns 37,907 shares in the company, valued at approximately $2,139,092.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Victoria L. Brown sold 2,698 shares of the company's stock in a transaction on Friday, June 17th. The stock was sold at an average price of $45.00, for a total transaction of $121,410.00. Following the completion of the transaction, the insider now owns 24,974 shares of the company's stock, valued at $1,123,830. The disclosure for this sale can be found here. In the last quarter, insiders have sold 101,789 shares of company stock valued at $4,748,310. 8.00% of the stock is owned by company insiders.

Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

APLS Stock News Headlines

Apellis Pharmaceuticals (NASDAQ:APLS) PT Raised to $86.00
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Up to $44.76
Apellis Pharmaceuticals Inc - Stock Chart
See More Headlines
Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

APLS Company Calendar

Last Earnings
11/08/2021
Today
8/07/2022
Next Earnings (Confirmed)
8/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APLS
Fax
N/A
Employees
476
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$70.36
High Stock Price Forecast
$102.00
Low Stock Price Forecast
$28.00
Forecasted Upside/Downside
+11.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
15 Analysts

Profitability

Net Income
$-746,350,000.00
Net Margins
-866.81%
Pretax Margin
-864.88%

Debt

Sales & Book Value

Annual Sales
$66.56 million
Book Value
$2.04 per share

Miscellaneous

Free Float
98,000,000
Market Cap
$6.75 billion
Optionable
Not Optionable
Beta
1.54














APLS Stock - Frequently Asked Questions

Should I buy or sell Apellis Pharmaceuticals stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Apellis Pharmaceuticals stock.
View analyst ratings for Apellis Pharmaceuticals
or view top-rated stocks.

What is Apellis Pharmaceuticals' stock price forecast for 2022?

15 brokerages have issued 1-year price targets for Apellis Pharmaceuticals' shares. Their APLS stock forecasts range from $28.00 to $102.00. On average, they anticipate Apellis Pharmaceuticals' stock price to reach $70.36 in the next twelve months. This suggests a possible upside of 11.1% from the stock's current price.
View analysts' price targets for Apellis Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Apellis Pharmaceuticals' stock performed in 2022?

Apellis Pharmaceuticals' stock was trading at $47.28 on January 1st, 2022. Since then, APLS shares have increased by 33.9% and is now trading at $63.33.
View the best growth stocks for 2022 here
.

When is Apellis Pharmaceuticals' next earnings date?

Apellis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Apellis Pharmaceuticals
.

How can I listen to Apellis Pharmaceuticals' earnings call?

Apellis Pharmaceuticals will be holding an earnings conference call on Monday, August 8th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced its quarterly earnings results on Monday, November, 8th. The company reported ($2.28) earnings per share for the quarter, missing analysts' consensus estimates of ($1.73) by $0.55. The firm earned $5.65 million during the quarter, compared to analysts' expectations of $2.32 million. Apellis Pharmaceuticals had a negative trailing twelve-month return on equity of 607.37% and a negative net margin of 866.81%. During the same quarter in the prior year, the company earned ($1.79) EPS.

What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?

18 employees have rated Apellis Pharmaceuticals CEO Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among Apellis Pharmaceuticals' employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend.

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an IPO on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (2.16%), Assenagon Asset Management S.A. (0.83%), Victory Capital Management Inc. (0.66%), Candriam S.C.A. (0.58%), Tekla Capital Management LLC (0.29%) and TD Asset Management Inc. (0.26%). Company insiders that own Apellis Pharmaceuticals stock include A Sinclair Dunlop, Adam J Townsend, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Pascal Deschatelets, Timothy Eugene Sullivan, Victoria L Brown and Victoria L Brown.
View institutional ownership trends for Apellis Pharmaceuticals
.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $63.33.

How much money does Apellis Pharmaceuticals make?

Apellis Pharmaceuticals (NASDAQ:APLS) has a market capitalization of $6.75 billion and generates $66.56 million in revenue each year. The company earns $-746,350,000.00 in net income (profit) each year or ($8.03) on an earnings per share basis.

How many employees does Apellis Pharmaceuticals have?

Apellis Pharmaceuticals employs 476 workers across the globe.

How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The official website for Apellis Pharmaceuticals is www.apellis.com. The company can be reached via phone at (617) 977-5700 or via email at investors@apellis.com.

This page (NASDAQ:APLS) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.